AnaptysBio, Inc. (ANAB) fair value analysis
Nasdaq · Updated 2026-09-07
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing therapeutic antibodies for immune and inflammatory diseases. The company is headquartered in San Diego, California and operates in the United States biopharmaceutical industry.
Valuation status
Awaiting full valuationANAB does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $53.66
- Sector
- Healthcare
- 12-month range
- $21.31–$66.76
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- High
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The upper-middle quarter of its range
What our data shows for ANAB
- Shares are trading in the upper third of their 12-month price range of $21.31–$66.76.
- The 14-day relative strength index sits at a neutral 53.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ANAB
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent ANAB news
TickrTrends' derived news-sentiment signal for ANAB is currently leaning positive, computed from recent coverage.
- Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference (manilatimes.net, 2026-09-01)
TickrTrends take: Anaptys' participation in the H.C. Wainwright conference represents an opportunity for the company to present its pipeline and business strategy to investors, which becomes particularly relevant given that TickrTrends is currently awaiting a full valuation assessment for the Healthcare sector company. For valuation-focused readers, such conference presentations typically provide updated financial guidance, clinical development timelines, or partnership announcements that can materially influence fair value estimates. Observers should monitor whether ANAB discloses information that could accelerate or modify the timeline for reaching a completed valuation. - GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control (finance.yahoo.com, 2026-08-17)
TickrTrends take: GSK's interest in acquiring AnaptysBio represents a potential catalyst that could influence how the market reassesses the company's asset value and strategic positioning within the Healthcare sector. With TickrTrends currently awaiting full valuation on ANAB, investors monitoring this situation should observe how acquisition discussions progress, as this could provide clarity on the company's intrinsic worth that the market has yet to fully price in. The terms and completion likelihood of any deal would be key factors in determining whether ANAB's valuation should shift materially from its current assessment stage. - AnaptysBio Stock: The Royalty Waterfall Is About To Reverse (NASDAQ:ANAB) (seekingalpha.com, 2026-07-29)
TickrTrends take: AnaptysBio operates in the Healthcare sector and currently has an awaiting full valuation designation from TickrTrends, meaning a comprehensive valuation assessment has not yet been completed. The reported reversal in the company's royalty waterfall structure represents a significant shift in its cash flow dynamics that would be particularly relevant to monitor as TickrTrends conducts its full valuation analysis. Investors focused on valuation metrics should track how this structural change impacts the company's revenue recognition and financial projections going forward.
What people are saying
Follow the ANAB conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ANAB stock undervalued?
ANAB does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is ANAB's TickrTrends verdict?
ANAB is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is ANAB overbought or oversold?
ANAB's 14-day RSI is in neutral territory - neither overbought nor oversold.